Clinical Trial Update: Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

This update describes a Phase 2 trial evaluating sequencing of Radium-223 and Docetaxel for symptomatic bone-only metastatic castration-resistant prostate cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Taxotere (docetaxel)
• Xofigo (radium-223 dichloride)

Snippet

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING